Humanized IgG1 monoclonal antibody targeting pyroglutamate-modified amyloid-beta (pGlu3-Aβ) plaques in early Alzheimer's disease. TRAILBLAZER-ALZ 2 trial showed slowing of cognitive decline through microglial-mediated plaque clearance.
Binds specifically to N-terminal pyroglutamate-modified amyloid-beta plaques (pGlu3-Aβ), facilitating removal via microglial-mediated phagocytosis. Achieves 15-25 centiloids reduction in measurable brain amyloid plaque, correlating with cognitive benefit.
Binds specifically to N-terminal pyroglutamate-modified amyloid-beta plaques (pGlu3-Aβ), facilitating removal via microglial-mediated phagocytosis. Achieves 15-25 centiloids reduction in measurable brain amyloid plaque, correlating with cognitive benefit.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
